| Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria CH Polman, SC Reingold, B Banwell, M Clanet, JA Cohen, M Filippi, ... Annals of neurology 69 (2), 292-302, 2011 | 8342 | 2011 |
| Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” CH Polman, SC Reingold, G Edan, M Filippi, HP Hartung, L Kappos, ... Annals of Neurology: Official Journal of the American Neurological …, 2005 | 5823 | 2005 |
| A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis CH Polman, PW O'Connor, E Havrdova, M Hutchinson, L Kappos, ... New England Journal of Medicine 354 (9), 899-910, 2006 | 3252 | 2006 |
| A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis L Kappos, EW Radue, P O'Connor, C Polman, R Hohlfeld, P Calabresi, ... New England Journal of Medicine 362 (5), 387-401, 2010 | 2618 | 2010 |
| Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis JA Cohen, F Barkhof, G Comi, HP Hartung, BO Khatri, X Montalban, ... New England Journal of Medicine 362 (5), 402-415, 2010 | 2310 | 2010 |
| Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria AJ Thompson, BL Banwell, F Barkhof, WM Carroll, T Coetzee, G Comi, ... The Lancet Neurology 17 (2), 162-173, 2018 | 1942 | 2018 |
| Defining the clinical course of multiple sclerosis: the 2013 revisions FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ... Neurology 83 (3), 278-286, 2014 | 1892 | 2014 |
| Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ... New England Journal of Medicine 367 (12), 1098-1107, 2012 | 1475 | 2012 |
| Oral fingolimod (FTY720) for relapsing multiple sclerosis L Kappos, J Antel, G Comi, X Montalban, P O'connor, CH Polman, T Haas, ... New England Journal of Medicine 355 (11), 1124-1140, 2006 | 1172 | 2006 |
| Ocrelizumab versus placebo in primary progressive multiple sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... New England Journal of Medicine 376 (3), 209-220, 2017 | 919 | 2017 |
| Randomized trial of oral teriflunomide for relapsing multiple sclerosis P O'Connor, JS Wolinsky, C Confavreux, G Comi, L Kappos, TP Olsson, ... New England Journal of Medicine 365 (14), 1293-1303, 2011 | 910 | 2011 |
| Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes L Kappos, CH Polman, MS Freedman, G Edan, HP Hartung, DH Miller, ... Neurology 67 (7), 1242-1249, 2006 | 908 | 2006 |
| Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci PL De Jager, X Jia, J Wang, PIW De Bakker, L Ottoboni, NT Aggarwal, ... Nature genetics 41 (7), 776, 2009 | 836 | 2009 |
| Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ... New England Journal of Medicine 376 (3), 221-234, 2017 | 808 | 2017 |
| Differential diagnosis of suspected multiple sclerosis: a consensus approach DH Miller, BG Weinshenker, M Filippi, BL Banwell, JA Cohen, ... Multiple Sclerosis Journal 14 (9), 1157-1174, 2008 | 732 | 2008 |
| Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial L Kappos, D Li, PA Calabresi, P O'Connor, A Bar-Or, F Barkhof, M Yin, ... The Lancet 378 (9805), 1779-1787, 2011 | 701 | 2011 |
| Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the … L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller, ... The Lancet 370 (9585), 389-397, 2007 | 660 | 2007 |
| Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis L Kappos The Lancet 352 (9139), 1491-1497, 1998 | 657 | 1998 |
| Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial PA Calabresi, EW Radue, D Goodin, D Jeffery, KW Rammohan, AT Reder, ... The Lancet Neurology 13 (6), 545-556, 2014 | 621 | 2014 |
| MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines M Filippi, MA Rocca, O Ciccarelli, N De Stefano, N Evangelou, L Kappos, ... The Lancet Neurology 15 (3), 292-303, 2016 | 594 | 2016 |
